Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers. UCB signed a definitive agreement to acquire…
UCB Expands Immunology Pipeline with Planned Acquisition of Candid Therapeutics, reinforcing its position in next-generation immunology with the addition of…
UCB inks $2B Candid buyout to join Gilead in autoimmune field. The Belgian drugmaker is buying Candid Therapeutics for $2 billion upfront with up to…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
UCB signed a definitive agreement to acquire privately held Candid Therapeutics for up to $2.2B ($2.0B upfront + $200M milestones), gaining lead asset cizutamig, a BCMAxCD3 bispecific T-cell engager in clinical development across more than 10 autoimmune indications. The deal builds UCB's immunology pipeline in B-cell-driven autoimmune diseases. Closing is anticipated in late Q2/early Q3 2026 subject to antitrust clearance.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB S.A. / Candid Therapeutics, Inc. (this deal) | 2026 | $2.2B | — |
| UCB S.A. / Ra Pharmaceuticals, Inc. | 2019 | $2.1B | — |
| UCB S.A. / Zogenix Inc. | 2022 | $1.9B | — |
| UCB S.A. / Neurona Therapeutics, Inc. | 2026 | $1.1B | — |
| UCB S.A. / Antengene Corporation Limited | 2026 | $1.2B | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
← Browse all deals · How we score deals
More: 2026 deals · UCB S.A. deals · Immunology deals